Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 1, 1998PEDIATRICS

Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants

View Full Paper
Ask AI
Bookmark
Share

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

A 1998 study studied this question.

synapsesocial.com/papers/6a7de98d968fa26fcacb53edhttps://doi.org/10.1542/peds.102.3.531
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia1998 · 227 citations
  2. 2Prophylactic Administration of Respiratory Syncytial Virus Immune Globulin to High-Risk Infants and Young Children1993 · 750 citations
  3. 3Respiratory Syncytial Virus Immune Globulin Intravenous: Indications for Use1997 · 107 citations
  4. 4Reduction of Respiratory Syncytial Virus Hospitalization Among Premature Infants and Infants With Bronchopulmonary Dysplasia Using Respiratory Syncytial Virus Immune Globulin Prophylaxis1997 · 454 citations